Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleArticle

THE PHARMACOLOGY OF THE ANTICHOLINERGIC QUATERNARY AMMONIUM COMPOUND BENZOMETHAMINE [N-DIETHYLA-MINOETHYL-N'-METHYL-BENZILAMIDE METHOBROMIDE (MC 3199)] WITH A NOTE ON THE TERTIARY AMINE ANALOGUE (MC 3137)

Richard C. Ursillo and Byron B. Clark
Journal of Pharmacology and Experimental Therapeutics May 1955, 114 (1) 54-62;
Richard C. Ursillo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Byron B. Clark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Benzomethamine has high anticholinergic activity, similar to that of atropine and Banthine, as shown by assays on acetylcholine-induced spasms of the rabbit ileum, and methacholine-induced chromodacryorrhea in rats. Its activity in dogs closely parallels that of atropine and Banthine in blocking acetylcholine-and vagal-induced hypotension, and also gastric contractions due to stimulation of the vagus.

Benzomethamine is less effective than Banthine in blocking the contractile response of the urinary bladder to pelvic nerve stimulation.

The inhibitory activity of benzomethamine against pilocarpine-induced salivation in rabbits is only two-tenths that of atropine.

Benzomethamine can produce ganglionic blockade in higher doses; in this respect it is only two-tenths as active as TEA and thus less active than Banthine. Its neuromuscular blocking potency appears to be very low.

The acute toxicity of benzomethamine in mice and dogs, and the subacute three-week toxicity in rats is low. No evidence of central nervous system toxicity was noted. In contrast, the tertiary amine analogue in the dog demonstrated pronounced central nervous system toxicity with anticholinergic doses.

Benzomethamine is active on oral administration in dogs although the orally effective dose is considerably larger than the intravenously effective dose. The pharmacological activity is discussed in relation to the absorption and physiological disposition. It is concluded that although benzomethamine is relatively stable metabolically, the factors of limited absorption, and rapid excretion emphasize the necessity of high intrinsic activity as a most important aspect of orally active anticholinergic quaternary ammonium agents.

Footnotes

    • Received January 14, 1955.

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics
Vol. 114, Issue 1
1 May 1955
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
THE PHARMACOLOGY OF THE ANTICHOLINERGIC QUATERNARY AMMONIUM COMPOUND BENZOMETHAMINE [N-DIETHYLA-MINOETHYL-N'-METHYL-BENZILAMIDE METHOBROMIDE (MC 3199)] WITH A NOTE ON THE TERTIARY AMINE ANALOGUE (MC 3137)
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

THE PHARMACOLOGY OF THE ANTICHOLINERGIC QUATERNARY AMMONIUM COMPOUND BENZOMETHAMINE [N-DIETHYLA-MINOETHYL-N'-METHYL-BENZILAMIDE METHOBROMIDE (MC 3199)] WITH A NOTE ON THE TERTIARY AMINE ANALOGUE (MC 3137)

Richard C. Ursillo and Byron B. Clark
Journal of Pharmacology and Experimental Therapeutics May 1, 1955, 114 (1) 54-62;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

THE PHARMACOLOGY OF THE ANTICHOLINERGIC QUATERNARY AMMONIUM COMPOUND BENZOMETHAMINE [N-DIETHYLA-MINOETHYL-N'-METHYL-BENZILAMIDE METHOBROMIDE (MC 3199)] WITH A NOTE ON THE TERTIARY AMINE ANALOGUE (MC 3137)

Richard C. Ursillo and Byron B. Clark
Journal of Pharmacology and Experimental Therapeutics May 1, 1955, 114 (1) 54-62;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • PST3093 Stimulates SERCA2a and Improves Cardiac Function
  • CRV431 Decreases Liver Fibrosis and Tumor Development
  • Antagonism of Immunostimulatory CpG-Oligodeoxynucleotides by 4-Aminoquinolines and Other Weak Bases: Mechanistic Studies
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics